CasNo.503612-47-3,Apixaban KDMF,(503612-47-3) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99%
Payment Terms : L/C,T/T

Keywords

Apixaban 503612-47-3 C25H25N5O4

Quick Details

Appearance:Off-White Powder
Application:Apixaban is used to treat adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE)
PackAge:Aluminium bag & Paper Drum
ProductionCapacity:500|Kilogram|Month
Storage:Room Temperature, Reserved in tightly containers and keep from light.
Transportation:Normal condition

Superiority:

Apixaban is used to treat adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE)

KDMF is available.

Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug.

Huarong Pharm has built platforms for the research, development and manufacturing of Building Blocks, Reference Compounds & Impurities, Natural products, APIs & Intermediates, Antibody-drug Conjugates (ADCs) and others. To maintain a high innovation efficiency, the company has continuously increased the investment on R&D facilities and state-of-the-art equipment in the past several years, including the establishment of kilogram GMP conditions plants and R&D centers.

Huarong Pharm adheres to our vision, our mission, and our value, keeping abreast of the current trend and state-of-the-art science and technologies of the global biopharmaceutical industry to serve our clients to the utmost satisfaction. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery.

At present, Huarong Pharm has successfully delivered innovative R&D products and services to more than 3,000 partners across the world. Our goal is to become a world-class leading company to support life science innovation and manufacturing.

Details:

Apixaban is the third new oral anticoagulant to go on sale, following dabigatran and rivaroxaban, and it has already been approved in Europe for preventing venous thromboembolism in patients undergoing elective hip or knee replacement surgery. Out of these three oral anticoagulants approved in Europe, compared to the current standard preventative treatment against venous thromboembolism, enoxaparin, rivaroxaban excelled in the record experiment, and apixaban excelled in the advance experiment. Rivaroxaban’s curative effects were slightly superior, but it caused more severe bleeding than apixaban. Researchers attributed these differences to medication time, as rivaroxaban was taken 6-8 hours after surgery in the record experiment, while apixaban was used 18 hours after surgery in the advance experiment. These drugs have better curative effect when used closer to time of surgery, but also have an increased bleeding risk. Clinical research showed that compared to a daily subdermal injection of 40mg enoxaparin, 2 oral 2.5mg dosages of apixaban had better preventative effects against venous thromboembolism following hip or knee replacement surgery and did not increase bleeding risk.